Tag: patients

Claret Capital Partners is providing growth funding of €43m as part of Inventiva’s €130m debt financing, to support its lead asset through Phase 3.

AMSTERDAM, 16 juin 2026 (GLOBE NEWSWIRE) -- Le professeur Ahmad AbuSalah, titulaire d’un doctorat, directeur du Digital Innovation Hub au King Faisal Specialist Hospital & Research Centre (KFSH), présente le modèle de l’hôpital visant à créer un écosystème d’intelligence artificielle appliquée en radiologie lors du congrès HLTH Europe 2026, qui se tiendra du 15 au 18 juin à Amsterdam. Il met en avant la manière dont l’IA peut passer d’un besoin clinique à un impact mesurable grâce à une gouvernance responsable, à l’intégration des flux de travail et à une adoption centrée sur l’humain.

SkinVision Pro connects AI-powered skin health assessments directly to medical practices, giving doctors structured information before the consultation begins. AMSTERDAM, June 16, 2026 /PRNewswire/...

REYKJAVIK, Iceland , June 16, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB) (“Alvotech” or the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the pricing of its previously announced underwritten public offering (the “Offering”) of 22,666,667 of its ordinary shares at an offering price of $3.75 per share. All ordinary shares to be sold in the Offering will be offered by Alvotech. The Offering is expected to close on or about June 17, 2026, subject to satisfaction of customary closing conditions. The Company has also granted the underwriters a 30-day option to purchase up to an additional 3,400,000 ordinary shares at the public offering price, less underwriting discounts and commissions. Before deducting the underwriting discounts and commissions and offering expenses, the Company expects to receive total gross proceeds of approximately $85 million from the Offering, or approximately $98 million if the underwriters exercise in full their option to purchase additional shares.

MHB018A demonstrated outstanding clinical activity in both active and chronic thyroid eye diseaseAt 450 mg Q4W, MHB018A achieved a remarkable 81% proptosis response at...

MORGANTOWN, W.Va., June 15, 2026 /PRNewswire/ -- Prominently featured in The Inner Circle, Haider Jaffrey, DDS is acknowledged as a Pinnacle Lifetime Member for his...

DERM Zero is a world-first - using Class III regulated medical device1 technology to deliver autonomous clinical grade skin cancer assessments from a standard...

MRD has scaled into a profitable, category-leading MRD diagnostics business, while Immune Medicine has built a differentiated discovery platform powered by proprietary immune data and AI

MRD has scaled into a profitable, category-leading MRD diagnostics business, while Immune Medicine has built a differentiated discovery platform powered by proprietary immune data and AI

Veteran healthcare leader, Bret Lyman, adds third territory as Utah's senior population continues to growWEST JORDAN, Utah, June 15, 2026 /PRNewswire/ -- Registered nurse and...

Target-specific licensing agreement enabling Antharis to advance proprietary dual-payload antibody-drug conjugate (ADC) programs using Lonza's site-specific ADC technologiesReinforces Antharis' and Lonza's position at the forefront...

The Boston Business Journal has named Interra Health to its 2026 Best Places to Work list.

DELRAY BEACH, Fla., June 15, 2026 /PRNewswire/ -- According to MarketsandMarkets™, the Companion Diagnostics Market is projected to grow from about USD 6.31 billion in...